HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Esperion Therapeutics, maintaining a price target of $16.
October 02, 2024 | 2:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Esperion Therapeutics, maintaining a price target of $16.
The reiteration of a Buy rating and maintenance of a $16 price target by HC Wainwright & Co. is a positive signal for investors, suggesting confidence in the company's future performance. This could lead to a short-term increase in ESPR's stock price as investors react to the analyst's endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100